Shanghai Serum Bio-Technology Co. Ltd. A

Sailun Bio announced that the company has received a GMP Compliance Certificate issued by the Food and Drug Administration of the Department of Health of the Republic of the Philippines. The production address is located at 1288 Huaqing Road, Qingpu District, Shanghai. The certified dosage form is injection, covering tetanus antitoxin, equine tetanus immunoglobulin F(ab')2, antivenom serum, and anti-rabies serum, valid until October 24, 2028. The announcement shows that passing this certification and obtaining the certificate marks that the production quality management system for the relevant products meets the requirements of the Philippine FDA, establishing the basic conditions for drug registration and commercial launch in the Philippines. The company plans to initiate registration of the relevant products in the Philippines and subsequent market promotion work, and gradually expand into the Southeast Asian market. The company also cautioned that the products still need to complete the local drug registration approval process in the Philippines, and the registration cycle, approval results, and final launch timing all remain uncertain. There are certain risks regarding whether commercialization can be successfully achieved and expected returns obtained.

Sailun Bio released its 2026 interim report on August 22, 2026. Total operating revenue was 104 million yuan, net profit attributable to the parent company was 35.6513 million yuan, and net cash inflow from operating activities was 8.0366 million yuan. The company's latest asset-liability ratio was 5.40 percent, up 1.83 percentage points from the previous quarter and up 2.87 percentage points from the same period last year. The latest gross margin was 78.28 percent, the latest return on equity was 3.18 percent, and diluted earnings per share was 0.33 yuan. The company's latest inventory turnover ratio was 0.54 times, and total asset turnover fell 0.45 percent from the same period last year. The company had 5,364 shareholders, and the top ten shareholders held 74.1553 million shares, accounting for 68.52 percent of total share capital.

Sailun Bio disclosed its 2026 interim report. In the first half, it achieved operating revenue of 104 million yuan, up 3.36% year on year. Net profit attributable to the parent company was 35.6513 million yuan, up 8.11% year on year. Basic earnings per share were 0.33 yuan. The company plans to distribute a cash dividend of 1.2 yuan, including tax, for every 10 shares.

Sailun Bio released its 2026 interim report, showing first-half net profit attributable to the parent of 35.65 million yuan, an increase of 8.1% year on year. Operating revenue was 104 million yuan, up 3.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 31.08 million yuan, up 9.0% year on year. Net operating cash flow was 8.04 million yuan, up 137.8% year on year. Second-quarter net profit attributable to the parent was 35.08 million yuan, up 20.1% year on year. The company said its business operations have not undergone major changes, remaining focused on the production, research and development, and sales of antiserum and antitoxin products. Research and development expenses rose 25.98% year on year.